Flurbiprofen eye drops recalled for insanitary facility conditions
Pharmacy Innovations is recalling Flurbiprofen 0.04% ophthalmic solution nationwide due to insanitary conditions at the manufacturing facility that compromise product sterility.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall without reported illnesses or injuries. The lack of sterility assurance in an ophthalmic product represents a risk-of-harm product where injury has not yet been reported, placing it at Score 3 (High) per the rubric.
Plain-English summary
Pharmacy Innovations is recalling Flurbiprofen 0.04% ophthalmic solution (eye drops) in 3-mL dropper bottles nationwide. The product code is t20221116@36.
The recall was initiated following an FDA inspection that revealed insanitary conditions at the manufacturing facility. These conditions raise concerns about the sterility of the product. Non-sterile eye drops can lead to serious eye infections and complications.
This product was distributed nationwide to healthcare facilities and pharmacies. Patients who have received this medication should contact their healthcare provider.
Consumers and healthcare providers who have this product should stop using it and contact Pharmacy Innovations or their healthcare provider for guidance on replacement or alternative medications.
The recalled product
- Product
- FLURBIPROFEN -CORN OIL- 0.04% (3ML DROPTAINER) OPH SOLUTION, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.
- Manufacturer
- Pharmacy Innovations
- Category
- Drug — Ophthalmic
- Hazard
- sterility-failure
- contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- t20221116@36
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27